Skip to main content

Coronavirus (COVID-19): Latest Updates | Visitation PoliciesVisitation PoliciesVisitation PoliciesVisitation PoliciesVisitation Policies | COVID-19 Testing | Vaccine InformationVaccine InformationVaccine Information

menu

Jodi Lipof, M.D.

Contact Information

Phone Numbers

Appointment: (585) 276-3000

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Locations

University of Rochester Medical Center
School of Medicine and Dentistry
601 Elmwood Ave, Box 704
Rochester, NY 14642

Faculty Appointments

Patient Care Setting

Cancer

Credentials

Specialties

    Education

    2015
    MD | George Washington University Hospital (USA)

    Post-doctoral Training & Residency

    07/01/2018 - 06/30/2021
    Fellowship in Hematology & Oncology at University of Rochester Medical Center

    06/25/2016 - 06/24/2018
    Residency in Internal Medicine at University of Rochester Medical Center

    06/10/2015 - 06/24/2016
    Internship in Internal Medicine at University of Rochester Medical Center

    VIEW ALL expand_more

    Clinical Trials

    Selinexor for the Treatment of Patients With Intermediate and High-Risk Smoldering Multiple Myeloma

    Lead Researcher: Jodi Lipof

    Selinexor is a drug that has been approved in the treatment of patients with symptomatic multiple myeloma. The standard of care for patients with Smoldering Multiple Myeloma remains observation, but there are numerous clinical trials investigating interventions to delay progression to multiple myeloma and prevent or delay disease related outcomes. A subset of patients with intermediate or high risk smoldering multiple myeloma have a much higher risk of progressive to multiple myeloma, while the low risk smoldering myeloma patient population has a much lower risk. This is a clinical trial investigating the use of low-dose selinexor in patients with intermediate to high-risk smoldering multiple myeloma. The investigators hypothesize that the use of selinexor in intermediate to high risk smoldering myeloma patients will help to delay progression of disease to symptomatic multiple myeloma.

    View Study Details

    Publications

    Journal Articles

    2021
    Lipof JJ, Huselton EJ, Zent CS, Evans A, Zhang B, Rothberg PG, Bennett JM. "A Case of Acute Eosinophilic Leukemia with a Novel 6 Mutation." Case reports in hematology.. 2021 2021:5574766. Epub 2021 Jul 03.

    8/2020
    Lipof JJ, Barr PM. "Early Progression of Follicular Lymphoma: Biology and Treatment." Hematology/oncology clinics of North America.. 2020 Aug; 34(4):757-769. Epub 2020 May 05.

    6/4/2018
    Lipof JJ, Loh KP, O'Dwyer K, Liesveld JL. "Allogeneic Hematopoietic Cell Transplantation for Older Adults with Acute Myeloid Leukemia." Cancers.. 2018 Jun 4; 10(6)Epub 2018 Jun 04.

    VIEW ALL PUBLICATIONS

    Reviews

    At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information.